Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Accumulated Expenses (2016 - 2025)

CytomX Therapeutics' Accumulated Expenses history spans 12 years, with the latest figure at $14.2 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 450.7% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $14.2 million, up 450.7%, while the annual FY2025 figure was $14.2 million, 450.7% up from the prior year.
  • Accumulated Expenses reached $14.2 million in Q4 2025 per CTMX's latest filing, up from $6.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $34.2 million in Q4 2021 to a low of $2.6 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $10.0 million, with a median of $6.8 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: crashed 76.46% in 2022, then soared 450.7% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $34.2 million in 2021, then plummeted by 76.46% to $8.1 million in 2022, then increased by 1.24% to $8.2 million in 2023, then tumbled by 68.41% to $2.6 million in 2024, then skyrocketed by 450.7% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Accumulated Expenses are $14.2 million (Q4 2025), $6.4 million (Q3 2025), and $11.5 million (Q2 2025).